Lexicon Pharmaceuticals, Inc. (LXRX) Rating Increased to Hold at Zacks Investment Research
According to Zacks, "Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones.
from Biotech News
0 Comments